![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CCL18 |
Gene summary for CCL18 |
![]() |
Gene information | Species | Human | Gene symbol | CCL18 | Gene ID | 6362 |
Gene name | C-C motif chemokine ligand 18 | |
Gene Alias | AMAC-1 | |
Cytomap | 17q12 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P55774 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6362 | CCL18 | C21 | Human | Oral cavity | OSCC | 4.02e-13 | 6.18e-01 | 0.2678 |
6362 | CCL18 | C30 | Human | Oral cavity | OSCC | 5.28e-20 | 6.71e-01 | 0.3055 |
6362 | CCL18 | C57 | Human | Oral cavity | OSCC | 3.17e-05 | 1.95e-01 | 0.1679 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003461218 | Oral cavity | OSCC | response to tumor necrosis factor | 143/7305 | 253/18723 | 1.09e-08 | 2.23e-07 | 143 |
GO:007135618 | Oral cavity | OSCC | cellular response to tumor necrosis factor | 128/7305 | 229/18723 | 1.49e-07 | 2.49e-06 | 128 |
GO:00343417 | Oral cavity | OSCC | response to interferon-gamma | 81/7305 | 141/18723 | 6.77e-06 | 7.43e-05 | 81 |
GO:00192214 | Oral cavity | OSCC | cytokine-mediated signaling pathway | 222/7305 | 472/18723 | 2.02e-04 | 1.35e-03 | 222 |
GO:00713465 | Oral cavity | OSCC | cellular response to interferon-gamma | 65/7305 | 118/18723 | 2.83e-04 | 1.79e-03 | 65 |
GO:005090010 | Oral cavity | OSCC | leukocyte migration | 176/7305 | 369/18723 | 3.80e-04 | 2.31e-03 | 176 |
GO:004308710 | Oral cavity | OSCC | regulation of GTPase activity | 165/7305 | 348/18723 | 7.94e-04 | 4.27e-03 | 165 |
GO:00603269 | Oral cavity | OSCC | cell chemotaxis | 146/7305 | 310/18723 | 2.13e-03 | 9.80e-03 | 146 |
GO:00705556 | Oral cavity | OSCC | response to interleukin-1 | 73/7305 | 143/18723 | 2.23e-03 | 1.00e-02 | 73 |
GO:00305959 | Oral cavity | OSCC | leukocyte chemotaxis | 110/7305 | 230/18723 | 3.86e-03 | 1.58e-02 | 110 |
GO:00713473 | Oral cavity | OSCC | cellular response to interleukin-1 | 58/7305 | 113/18723 | 5.14e-03 | 2.01e-02 | 58 |
GO:00434107 | Oral cavity | OSCC | positive regulation of MAPK cascade | 213/7305 | 480/18723 | 8.71e-03 | 3.16e-02 | 213 |
GO:00703716 | Oral cavity | OSCC | ERK1 and ERK2 cascade | 150/7305 | 330/18723 | 9.47e-03 | 3.38e-02 | 150 |
GO:007162110 | Oral cavity | OSCC | granulocyte chemotaxis | 62/7305 | 125/18723 | 1.02e-02 | 3.52e-02 | 62 |
GO:00703724 | Oral cavity | OSCC | regulation of ERK1 and ERK2 cascade | 140/7305 | 309/18723 | 1.34e-02 | 4.46e-02 | 140 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
CCL18 | ACKR1 | CCL18_ACKR1 | CCL | Breast | Healthy |
CCL18 | ACKR1 | CCL18_ACKR1 | CCL | Breast | IDC |
CCL18 | ACKR1 | CCL18_ACKR1 | CCL | Cervix | CC |
CCL18 | ACKR1 | CCL18_ACKR1 | CCL | Cervix | Precancer |
CCL18 | ACKR1 | CCL18_ACKR1 | CCL | HNSCC | OSCC |
CCL18 | ACKR1 | CCL18_ACKR1 | CCL | HNSCC | Precancer |
CCL18 | ACKR1 | CCL18_ACKR1 | CCL | Lung | AAH |
CCL18 | ACKR1 | CCL18_ACKR1 | CCL | Lung | AIS |
CCL18 | ACKR1 | CCL18_ACKR1 | CCL | Lung | IAC |
CCL18 | ACKR1 | CCL18_ACKR1 | CCL | Lung | Precancer |
CCL18 | ACKR1 | CCL18_ACKR1 | CCL | THCA | ADJ |
CCL18 | ACKR1 | CCL18_ACKR1 | CCL | THCA | Cancer |
CCL18 | ACKR1 | CCL18_ACKR1 | CCL | THCA | Precancer |
CCL18 | ACKR1 | CCL18_ACKR1 | CCL | THCA | PTC |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CCL18 | SNV | Missense_Mutation | novel | c.46N>A | p.Ala16Thr | p.A16T | P55774 | protein_coding | tolerated(0.21) | benign(0.042) | TCGA-CG-4460-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6362 | CCL18 | DRUGGABLE GENOME | IMMUNOMODULATORS | 12161279 | ||
6362 | CCL18 | DRUGGABLE GENOME | LD78 | 9233607 |
Page: 1 |